Minireview: Epigenetic programming of diabetes and obesity: Animal models

Yoshinori Seki, Lyda Williams, Patricia M. Vuguin, Maureen J. Charron

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

A growing body of evidence suggests that the intrauterine (IU) environment has a significant and lasting effect on the long-term health of the growing fetus and the development of metabolic disease in later life as put forth in the fetal origins of disease hypothesis. Metabolic diseases have been associated with alterations in the epigenome that occur without changes in the DNA sequence, such as cytosine methylation of DNA, histone posttranslational modifications, and microRNA. Animal models of epigenetic modifications secondary to an altered IU milieu are an invaluable tool to study the mechanisms that determine the development of metabolic diseases, such as diabetes and obesity. Rodent and nonlitter bearing animals are good models for the study of disease, because they have similar embryology, anatomy, and physiology to humans. Thus, it is feasible to monitor and modify the IU environment of animal models in order to gain insight into the molecular basis of human metabolic disease pathogenesis. In this review, the database of PubMed was searched for articles published between 1999 and 2011. Key words included epigenetic modifications, IU growth retardation, small for gestational age, animal models, metabolic disease, and obesity. The inclusion criteria used to select studies included animal models of epigenetic modifications during fetal and neonatal development associated with adult metabolic syndrome. Experimental manipulations included: changes in the nutritional status of the pregnant female (calorie-restricted, high-fat, or low-protein diets during pregnancy), as well as the father; interference with placenta function, or uterine blood flow, environmental toxin exposure during pregnancy, as well as dietary modifications during the neonatal (lactation) as well as pubertal period. This review article is focused solelyonstudies in animal models that demonstrate epigenetic changes that are correlated with manifestation of metabolic disease, including diabetes and/or obesity.

Original languageEnglish (US)
Pages (from-to)1031-1038
Number of pages8
JournalEndocrinology
Volume153
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Metabolic Diseases
Epigenomics
Animal Models
Obesity
Histone Code
Fetal Diseases
Diet Therapy
Pregnancy
Protein-Restricted Diet
Embryology
Fetal Growth Retardation
Cytosine
Environmental Exposure
DNA Methylation
Post Translational Protein Processing
Fetal Development
Nutritional Status
MicroRNAs
Lactation
PubMed

ASJC Scopus subject areas

  • Endocrinology

Cite this

Minireview : Epigenetic programming of diabetes and obesity: Animal models. / Seki, Yoshinori; Williams, Lyda; Vuguin, Patricia M.; Charron, Maureen J.

In: Endocrinology, Vol. 153, No. 3, 03.2012, p. 1031-1038.

Research output: Contribution to journalArticle

Seki, Yoshinori ; Williams, Lyda ; Vuguin, Patricia M. ; Charron, Maureen J. / Minireview : Epigenetic programming of diabetes and obesity: Animal models. In: Endocrinology. 2012 ; Vol. 153, No. 3. pp. 1031-1038.
@article{4673cfa267764c50941e951f2ac54fc2,
title = "Minireview: Epigenetic programming of diabetes and obesity: Animal models",
abstract = "A growing body of evidence suggests that the intrauterine (IU) environment has a significant and lasting effect on the long-term health of the growing fetus and the development of metabolic disease in later life as put forth in the fetal origins of disease hypothesis. Metabolic diseases have been associated with alterations in the epigenome that occur without changes in the DNA sequence, such as cytosine methylation of DNA, histone posttranslational modifications, and microRNA. Animal models of epigenetic modifications secondary to an altered IU milieu are an invaluable tool to study the mechanisms that determine the development of metabolic diseases, such as diabetes and obesity. Rodent and nonlitter bearing animals are good models for the study of disease, because they have similar embryology, anatomy, and physiology to humans. Thus, it is feasible to monitor and modify the IU environment of animal models in order to gain insight into the molecular basis of human metabolic disease pathogenesis. In this review, the database of PubMed was searched for articles published between 1999 and 2011. Key words included epigenetic modifications, IU growth retardation, small for gestational age, animal models, metabolic disease, and obesity. The inclusion criteria used to select studies included animal models of epigenetic modifications during fetal and neonatal development associated with adult metabolic syndrome. Experimental manipulations included: changes in the nutritional status of the pregnant female (calorie-restricted, high-fat, or low-protein diets during pregnancy), as well as the father; interference with placenta function, or uterine blood flow, environmental toxin exposure during pregnancy, as well as dietary modifications during the neonatal (lactation) as well as pubertal period. This review article is focused solelyonstudies in animal models that demonstrate epigenetic changes that are correlated with manifestation of metabolic disease, including diabetes and/or obesity.",
author = "Yoshinori Seki and Lyda Williams and Vuguin, {Patricia M.} and Charron, {Maureen J.}",
year = "2012",
month = "3",
doi = "10.1210/en.2011-1805",
language = "English (US)",
volume = "153",
pages = "1031--1038",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Minireview

T2 - Epigenetic programming of diabetes and obesity: Animal models

AU - Seki, Yoshinori

AU - Williams, Lyda

AU - Vuguin, Patricia M.

AU - Charron, Maureen J.

PY - 2012/3

Y1 - 2012/3

N2 - A growing body of evidence suggests that the intrauterine (IU) environment has a significant and lasting effect on the long-term health of the growing fetus and the development of metabolic disease in later life as put forth in the fetal origins of disease hypothesis. Metabolic diseases have been associated with alterations in the epigenome that occur without changes in the DNA sequence, such as cytosine methylation of DNA, histone posttranslational modifications, and microRNA. Animal models of epigenetic modifications secondary to an altered IU milieu are an invaluable tool to study the mechanisms that determine the development of metabolic diseases, such as diabetes and obesity. Rodent and nonlitter bearing animals are good models for the study of disease, because they have similar embryology, anatomy, and physiology to humans. Thus, it is feasible to monitor and modify the IU environment of animal models in order to gain insight into the molecular basis of human metabolic disease pathogenesis. In this review, the database of PubMed was searched for articles published between 1999 and 2011. Key words included epigenetic modifications, IU growth retardation, small for gestational age, animal models, metabolic disease, and obesity. The inclusion criteria used to select studies included animal models of epigenetic modifications during fetal and neonatal development associated with adult metabolic syndrome. Experimental manipulations included: changes in the nutritional status of the pregnant female (calorie-restricted, high-fat, or low-protein diets during pregnancy), as well as the father; interference with placenta function, or uterine blood flow, environmental toxin exposure during pregnancy, as well as dietary modifications during the neonatal (lactation) as well as pubertal period. This review article is focused solelyonstudies in animal models that demonstrate epigenetic changes that are correlated with manifestation of metabolic disease, including diabetes and/or obesity.

AB - A growing body of evidence suggests that the intrauterine (IU) environment has a significant and lasting effect on the long-term health of the growing fetus and the development of metabolic disease in later life as put forth in the fetal origins of disease hypothesis. Metabolic diseases have been associated with alterations in the epigenome that occur without changes in the DNA sequence, such as cytosine methylation of DNA, histone posttranslational modifications, and microRNA. Animal models of epigenetic modifications secondary to an altered IU milieu are an invaluable tool to study the mechanisms that determine the development of metabolic diseases, such as diabetes and obesity. Rodent and nonlitter bearing animals are good models for the study of disease, because they have similar embryology, anatomy, and physiology to humans. Thus, it is feasible to monitor and modify the IU environment of animal models in order to gain insight into the molecular basis of human metabolic disease pathogenesis. In this review, the database of PubMed was searched for articles published between 1999 and 2011. Key words included epigenetic modifications, IU growth retardation, small for gestational age, animal models, metabolic disease, and obesity. The inclusion criteria used to select studies included animal models of epigenetic modifications during fetal and neonatal development associated with adult metabolic syndrome. Experimental manipulations included: changes in the nutritional status of the pregnant female (calorie-restricted, high-fat, or low-protein diets during pregnancy), as well as the father; interference with placenta function, or uterine blood flow, environmental toxin exposure during pregnancy, as well as dietary modifications during the neonatal (lactation) as well as pubertal period. This review article is focused solelyonstudies in animal models that demonstrate epigenetic changes that are correlated with manifestation of metabolic disease, including diabetes and/or obesity.

UR - http://www.scopus.com/inward/record.url?scp=84857402885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857402885&partnerID=8YFLogxK

U2 - 10.1210/en.2011-1805

DO - 10.1210/en.2011-1805

M3 - Article

C2 - 22253432

AN - SCOPUS:84857402885

VL - 153

SP - 1031

EP - 1038

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 3

ER -